KMT2A and acute myeloid leukemia: It was found that the integrated therapy of KO-539 with BET, CDK6-6, or BCL2-2 inhibitors could induce in vitro synergies that are lethally induced by MLL1-r or mtNPM1 on AML cells [34,35].